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Abstract
Background: Type 2 diabetes mellitus is associated with cognitive dysfunction and an increased risk of dementia.
Linagliptin is a glucose-lowering agent of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class that is of particular
interest for the prevention of accelerated cognitive decline, because it may potentially benefit the brain through
pleiotropic effects, beyond glucose lowering. This paper presents the design of a study that aims to establish if
linagliptin is superior to the sulfonylurea glimepiride in the prevention of accelerated cognitive decline in patients
with type 2 diabetes mellitus.
Methods: The cognition substudy is an integral part of the ongoing event-driven, randomised, double blind
CARdiOvascular safety of LINAgliptin (CAROLINA®) trial, which evaluates the effect of treatment with linagliptin
versus glimepiride on cardiovascular outcomes. CAROLINA® includes patients with type 2 diabetes mellitus with
sub-optimal glycaemic control at elevated cardiovascular risk. The substudy will evaluate patients randomised and
treated who have a baseline Mini Mental State Examination (MMSE) score ≥ 24, documented years of formal
education with at least one valid cognitive assessment at baseline and during follow-up. The primary cognitive
outcome is the occurrence of accelerated cognitive decline at the end of follow-up. The two treatment groups will
be compared by using a logistic regression. Accelerated cognitive decline is defined as a rate of cognitive decline
that falls at or below the 16th percentile of decline for the whole cohort on either the MMSE or a combined score
of the trail making and verbal fluency test. Potential confounders are taken into account at an individual patient
level, using a regression based index.
Discussion: Between December 2010 and December 2012, 6042 patients were randomised and treated with either
linagliptin (5 mg) or glimepiride (1-4 mg) once daily in CAROLINA®. Cognitive tests were conducted in nearly 4500
participants at baseline and are scheduled for two subsequent assessments, after 160 weeks of follow-up and end of
follow-up. This substudy of the ongoing CAROLINA® trial will establish if linagliptin is superior to glimepiride in the
prevention of accelerated cognitive decline in patients with type 2 diabetes mellitus. Final results are expected in 2019.
Trial registration: ClinicalTrials.gov Identifier: NCT 01243424.
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Background
Type 2 diabetes mellitus (T2DM) is a rising public
health concern with over 400 million cases worldwide in
2015 and an estimated number of over 600 million cases
by 2040 [1]. Prevention of long-term complications is a
major focus of diabetes treatment. In this respect, cogni-
tive dysfunction and dementia are diabetes-associated
complications that receive increasing attention [2, 3]. It
is well recognised that the risk of dementia is increased
in people with T2DM [4]. A recent meta-analysis evalu-
ated 20 studies reporting on the risk of any type of
dementia, 20 on Alzheimer’s disease and 13 on vascular
dementia (VaD), including a total of 1,148,041 partici-
pants, of whom 89,708 had diabetes. The pooled relative
risk (95% CI) for dementia in people with diabetes was
1.73 (1.65–1.82), for Alzheimer’s disease 1.56 (1.41–1.73)
and for VaD 2.27 (1.94–2.66) [5] as compared to people
without. In addition, diabetes is associated with more
subtle cognitive changes, that are referred to as diabetes-
associated cognitive decrements [2, 3].
Accelerated cognitive decline is a cause for concern in
patients with T2DM, yet no preventive treatment has been
established. Lifestyle, vascular, and diabetes-specific risk
factors present many promising targets for prevention and
treatment [2, 6, 7]. These include management of gly-
caemic control and avoidance of severe hypoglycaemic
events [8]. Previous observational studies that examined
the effect of glucose-lowering treatments (including met-
formin, sulfonylureas, thiazolidinedione, insulin or a com-
bination of these) on the risk of cognitive decline have not
demonstrated consistent findings [2]. Because observa-
tional studies have a substantial risk of bias, randomised
controlled trials (RCTs) are needed; unfortunately few
have been performed. A recent meta-analysis summarised
the results of five well conducted RCTs on the effect of
intensive versus standard glycaemic control on cognitive
decline in patients with T2DM, involving over 24,000 par-
ticipants [9]. This pooled analysis showed that intensive
glycaemic control was not associated with a slower rate of
cognitive decline, compared with standard glycaemic
control, although there was some heterogeneity among
studies [9]. These previous RCTs have in common that
they used mean cognitive performance as their primary
outcome, which may include many participants with little
or no cognitive decline. Although duration of follow-up of
the studies ranged from 3 to 6 years [9], the actual average
decline in mean cognitive performance was limited
[10–13]. Over the past years it has become clear, also
from observational studies, that the average decline in
cognition over time associated with diabetes [2] is
relatively slow, limiting the sensitivity of follow up
studies to detect meaningful differences. Importantly
however, among patients with T2DM there is heterogen-
eity in the rate of cognitive decline, where some have
accelerated decline which in some cases progress to
dementia. For example, in a large cohort of patients with
T2DM over the age of 60 years, annual incidence of
dementia of 2.6% was reported [14]. It might therefore be
more appropriate - and clinically meaningful with regards
to establishing interventions - to focus on occurrence of
accelerated cognitive decline in individual patients. Such
an approach is chosen in the CAROLINA®-cognition sub-
study. Interestingly, the ORIGIN study (which studied
effects on outcomes of intensive glucose lowering with
insulin glargine) did a post-hoc analysis using this ap-
proach in the ORIGIN MIND substudy and observed a
modest, albeit statistically non-significant, benefit of inten-
sive glycaemic control [10] versus standard care.
Dipeptidyl peptidase-IV (DPP-IV) inhibitors improve
glycaemic control by inhibiting the enzyme DPP-IV
thereby enhancing the incretin effects, i.e., increasing the
availability of active glucagon-like peptide (GLP)-1 and
glucose-dependent insulinotropic polypeptide (GIP),
which are secreted from the intestine after a meal. In the
presence of hyperglycaemia, these hormones promote
glucose-dependent insulin secretion and reduce gluca-
gon secretion [15]. Beyond their effects on DPP-IV activ-
ity and glucose, several preclinical studies suggest anti-
inflammatory, anti-atherosclerotic and neuroprotective
effects that might be relevant in the context of prevent-
ing accelerated cognitive decline [15–19]. Experimental
studies also show promising results of incretin-based
therapies in models of Alzheimer’s disease and stroke
[17]. These potential pleiotropic modes of action make
DPP-IV inhibitors attractive candidate drugs to prevent
accelerated cognitive decline in T2DM. Recently, an
observational study found that increased plasma DPP-IV
activity was associated with a high risk of mild cognitive
impairment in elderly patients with T2DM [20], provid-
ing further support to test a strategy of modulating
DPP-IV activity in T2DM to prevent cognitive impair-
ment. The international, randomised, double blinded
CARdiOvascular safety of LINAgliptin (CAROLINA®)
trial is designed to provide a long-term evaluation of
treatment durability and cardiovascular safety of treat-
ment with the DPP-IV inhibitor linagliptin compared to
the currently widely used sulfonylurea (SU) glimepiride
[21, 22]. Linagliptin is a once-daily, DPP-IV inhibitor
with a xanthine-based structure that is characterised by
a pharmacological profile distinct from other drugs in
this class [23] largely due to its non-renal route of
elimination (80% hepatic versus 5% renal) [24]. The
cognition substudy is an integrated part of CAROLINA®.
Objectives
The primary objective of the CAROLINA®-cognition
substudy is to investigate if the proportion of partici-
pants with accelerated cognitive decline is lower in the
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group randomised to treatment with linagliptin com-
pared to the group randomised to glimepiride after
160 weeks, or at end of follow-up.
Secondary objectives
Unravelling the processes that underlie cognitive decline
in T2DM is important to support future prevention
strategies. Secondary objectives are therefore:
1) At baseline: to explore associations between
characteristic features of T2DM (i.e., glycaemic and
anthropometric parameters), cardiovascular risk
factors (i.e., blood pressure and lipid levels) and
cognitive performance
2) Longitudinal: to explore associations between
baseline characteristic features of T2DM,
cardiovascular risk factors – and changes in these
factors over time – and cognitive decline during
follow-up
3) Longitudinal: to explore the associations between
baseline mood – and changes in mood over time -
and cognitive decline during follow-up
Methods
Design and sample
The CAROLINA® trial is a randomised, active compara-
tor, double blind study to evaluate the cardiovascular
safety of linagliptin versus glimepiride in patients with
T2DM at elevated cardiovascular risk. Patients were
randomised between 2010 and 2012 from approximately
600 trial centres in 43 different countries. Key inclusion
criteria are shown in Table 1.
CAROLINA® is an event driven study. It is planned to
run until a minimum of 631 confirmed Major Adverse
Cardiovascular Events (MACE) have been accrued. MACE
include cardiovascular death (including fatal stroke and
fatal myocardial infarction (MI)), non-fatal MI (excluding
silent MI) and non-fatal stroke. The estimated study dur-
ation is about 432 weeks. For more detailed information
about the CAROLINA® main study see the Boehringer
Ingelheim trial protocol (1218.74, Clintrial.gov id
NCT01243424) and the previously published paper on
the design and baseline characteristics [21].
CAROLINA cognition substudy
Cognitive tests are conducted at baseline, after 160 weeks
and at planned end of follow-up (or at permanent
treatment-discontinuation). To be eligible for cognitive
testing in this substudy, participants need to live in a
country that have a native language built on the Latin
alphabet, due to psychometric test-battery validation.
Participants are included in the analysis data-set of the
CAROLINA®-cognition substudy of baseline data if they
are randomised and treated with at least one dose of
study drug and have at least one valid cognitive assess-
ment at baseline and documented years of formal educa-
tion. For the analyses of follow-up data in addition at
least one valid cognitive assessment during follow-up
Table 1 Key inclusion criteria CAROLINA®
Insufficient glycaemic control defined as one of the criteria (A or B) AND Elevated risk of cardiovascular events defined as any (one or more)
of the criteria (A, B, C or D)
(A) HbA1c 6.5 - 8.5% (48–69 mmol/mol) while patient is treatment
naïve or treated with:
(I) Metformin monotherapy
(II) α-Glucosidase inhibitor monotherapy (e.g. acarbose, voglibose)
(III) Metformin plus α-glucosidase inhibitor (e.g. acarbose, voglibose)
(B) HbA1c 6.5 - 7.5% (48–58 mmol/mol) while patient is treated with:
(I) SU monotherapy
(II) Glinide monotherapy (e.g. repaglinide, nateglinide)
(III) Metformin plus SU (for a maximum of 5 years)
(IV) Metformin plus glinide (for a maximum of 5 years)
(V) α-Glucosidase inhibitor plus SU (for a maximum of 5 years)
(VI) α-Glucosidase inhibitor plus glinide (for a maximum of 5 years)
(A) Previous vascular disease:
(I) MI (>6 weeks prior to informed consent IC)
(II) Documented coronary artery disease (⩾50% luminal diameter
narrowing of left main coronary artery or in at least two major
coronary arteries in angiogram)
(III) Percutaneous coronary intervention (>6 weeks prior to IC)
(IV) Coronary artery bypass grafting (>4 years prior to IC) or with
recurrent angina following surgery
(V) Ischaemic or haemorrhagic stroke (>3 months prior to IC)
(VI) Peripheral occlusive arterial disease
(B) Evidence of vascular-related end-organ damage:
(I) Moderately impaired renal function (as defined by MDRD
formula) with eGFR 30–59 ml/min/1.73 m2
(II) Random spot urinary albumin:creatinine ratio ⩾30 μg/mg
in two of three unrelated specimens in the previous 12 months.
(III) Proliferative retinopathy defined as retinal neovascularization
or previous retinal laser coagulation therapy
(C) Age ≥ 70 years
(D) At least two of the following cardiovascular risk factors:
(I) T2DM duration >10 years
(II) Systolic BP > 140 mmHg (or on at least 1 BP-lowering
treatment) <6 months prior to IC
(III) Current daily cigarette smoking
(IV) LDL-cholesterol ⩾ 135 mg/dL (3.5 mmol/L) (or specific current
treatment for this lipid abnormality) <6 months prior to IC
Table adapted from Marx et al. 2015 [21]. CAROLINA: CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes; IC: informed consent;
T2DM: type 2 diabetes mellitus; BP: blood pressure; SU: sulphonylurea; MI: myocardial infarction; MDRD: modified diet in renal disease; eGFR: estimated glomerular
filtration rate
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and baseline Mini Mental State Examination (MMSE)
score ≥ 24 is required as illustrated in Fig. 1. An over-
view of the CAROLINA cognition substudy according to
the "SPIRIT checklist" is provided in Additional file 1.
Cognitive assessment and psychometric tests
This cognitive assessment included a cognitive paper
based test battery that is brief and easy to administer in
a standardised way. The tests are sensitive to relatively
mild cognitive changes in T2DM, well standardised and
validated, and available in multiple languages (using the
modern Latin alphabet). The specific tests selected were:
1. Mini Mental State Examination (MMSE). The
MMSE is a screening instrument that was developed
to determine whether older adults have cognitive
impairments [25]. It consists of a range of items
assessing orientation, memory for words, drawing,
backward counting and semantic knowledge, with a
maximum score of 30. The MMSE takes
approximately five minutes to administer and
participating centres use country-specific validated
questionnaires of the MMSE. A cut-off of <24 is
widely used, and has been accepted, as indicating the
presence of cognitive impairment [26]. A limitation
of the MMSE is that it is insensitive to cognitive
decrements in domains affected by vascular-related
cognitive impairment, in particular attention, executive
functioning and information processing speed [27].
Therefore two additional tests that tap into these
domains were included - the Trail Making Test (TMT)
and the verbal fluency test (VFT). Although the TMT
and the VFT measure different cognitive processes,
there is a clear consensus in cognitive theory and
clinical practice that both tests assess important aspects
of speed, attention and executive functioning [28].
2. TMT. The TMT is a test of scanning, visuomotor
tracking, divided attention and cognitive flexibility
[29]. The test requires a subject to ‘connect-the-dots’
of 25 consecutive targets on a sheet of paper. Two
versions are available: A, in which the targets are all
numbers (1,2,3, etc.), and B, in which the subject
alternates between numbers and letters (1, A, 2, B,
etc.). The goal is to finish the test as quickly as
Fig. 1 overview design CAROLINA®-cognition substudy. Abbreviations: FU: follow-up, A&E score: Attention and Executive functioning score, MMSE:
Mini Mental State Examination, VFT: Verbal Fluency Test, TMT: Trail Making Test, CES-D: Centre for Epidemiologic Studies Depression Scale
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possible, and the time taken to complete the test is
recorded. The maximum score (i.e. 300 s) is assigned
to patients who are unable to complete the test
within five minutes. The TMT is highly sensitive to
the presence of cognitive impairment [30]. The TMT B
is sensitive to T2DM-associated cognitive decrements,
and in older individuals test performance clearly
decreases over time [31–33]. The English versions of
the TMT test instructions were translated into the local
languages. Potential effects of translation of the test
instructions on test difficulty, although unlikely, cannot
be ruled out a priori and therefore will be tested (see
sensitivity analyses, Table 2).
3. VFT. The VFT requires a subject to generate as
many words as possible in 60 s. The category version
(semantic fluency) requires generation of words
from a certain category (e.g. animals), the letter
version (phonemic fluency) requires generation of
words starting with a specific letter. The tests are
sensitive to the effects of ageing and performance is
clearly affected in T2DM [27, 32, 33]. It is viewed as
a sensitive indicator of (even mild) cognitive
dysfunction. In CAROLINA, the category animals
and the letters F, A and S are used for all languages.
The number of words/animals after 15 s and after
60 s are recorded. The test takes approximately five
minutes to complete. The English versions of the
test instructions were translated into the local
languages. Because of word-frequency differences
between different Latin-based languages the letters
FAS will not yield identical performance in different
languages. However, FAS-equivalent letter combina-
tions were available in a minority of languages only.
Therefore, we chose to calculate a language-specific
correction score (see analysis).
For the purpose of assessing effects on Attention and
Executive functioning, the TMT and the VFT are com-
bined to one composite score for Attention and Executive
functioning (the A&E score). The A&E score is calculated
as follows:
1) The VFT scores for the letters F, A and S in 60 s are
averaged to one VFT letter fluency score.
2) The VFT is corrected for language influences by
calculating least square (LS) means in an analysis of
covariance (ANCOVA) model including age, gender,
years of formal education, race and language as
independent variables. The LS means for language
are derived and then compared to one reference
language (English), i.e. correction factors are
calculated for each language separately (LSmean
language/ LSmean English). Correction factors will
be calculated for the three letters F, A and S taken
together, and for the category fluency (i.e. animals)
separately. The VFT scores of each participant are
then corrected by multiplying the score with the
corresponding correction factor. After correction,
the scores are converted into z-scores. Z-scores are
used to standardise raw test scores and make them
directly comparable, z-scores are calculated as
follows: (individual raw test score – mean baseline
test score study population)/ baseline standard
deviation.
3) The corrected VFT letter fluency and the VFT
category fluency z-scores (both after 60 s) are
averaged to one VFT overall score, where the letter
fluency and the category fluency each account for 50%.
4) The TMT ratio is calculated, providing an index for
executive functioning: (TMT B –TMTA) / TMT A.
5) The TMT ratio and VFT overall score are converted
into z-scores.
6) The mean of the TMT ratio and VFT overall z-
scores is used to generate one composite score for
attention and executive functioning. In secondary
analysis the TMT and VFT will be analysed
separately to control for potential test-specific
effects.
Table 2 Sensitivity analyses for the primary outcome
Reason sensitivity analysis How is the sensitivity analysis performed?
Check the influence of inappropriate inclusion, potentially
confounding co-morbid conditions and trial medication use
Participants will be excluded from the analysis if:
• major inclusion or exclusion criteria are violated
• incorrect trial medication is taken
• major neurological or psychiatric disease was present at baseline
Check the influence of classifying participants who did not
understand the instructions at follow-up as having
accelerated cognitive decline
The last observation carried forward method will be used for patients
with missing MMSE and A&E RBI-scores at follow-up if the reason for
missing is the inability of the patient to understand the instructions
(instead of classifying them as having accelerated cognitive decline)
Check for bias by differential lost to follow-up (worst case scenario) All patients with missing MMSE and A&E RBI-scores at follow-up will
be considered to have accelerated cognitive decline
Investigate the impact of further baseline variables on the RBI
score result, Check for confounding by depression symptoms
Age, gender, years of formal education, race, ethnicity and language
and CES-D (score < 16, ≥16) are included as covariates in the logistic
regression analysis
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As depression is a confounder to cognitive perform-
ance, participants also complete a depression question-
naire. In the CAROLINA® cognition substudy, we use
the Centre for Epidemiologic Studies Depression Scale
(CES-D), a widely used and validated 20-item question-
naire on depressive symptoms over the past week [34].
A score of ≥16 is indicative of a depression [35]. When-
ever available in a county, the validated version of the
CES-D was used. For languages were no validated version
was available, a back translation was created and verified.
As both too high or too low blood glucose values can
affect cognitive performance, self-monitoring of blood glu-
cose (SMBG) values levels are to be measured (finger prick)
prior to each cognitive assessment. Whenever the SMBGis
not within 4 – 13 mmol/L the cognitive assessment is post-
poned. If values >3 or <18 mmol/L the finger prick could
be repeated after at least one hour provided that the
SMBGis within the 4–13 mmol/L range. In case glucose
values ≤3 or ≥18 mmol/L glycemic management should be
reviewed and the assessment postponed 1–7 days.
To optimise the quality of the cognitive outcomes,
face-to-face meetings including training for examiners
were organised in conjunction with the study start-up
meetings. In addition, written step-by-step instructions
for the (preparation of the) test assessment were
provided. All tests were administered by the investigator
or designated site-personnel who were all fluent in the
language of test administration. The language in which
the tests are performed is captured in the CRF. It is also
recorded whether this language is the native language of
the patient. If the tests are not performed in patient’s
native language the VFT scores are considered to be
invalid and are set to missing.
The investigator or designated site-personnel can
add a comment to the test score if they doubt the
validity of the test. All those comments are independ-
ently reviewed by two members of the analysis team
and categorised into whether those have an impact
on the test score results (“valid” or “not valid” test
score results). Discrepancies are resolved by means of
discussion and before unblinding of the study. All test
scores considered as not valid are set to missing. If the
comments indicate that all tests of the patient are invalid
(e.g. patient is illiterate) the patient is excluded from CAR-
OLINA®-cognition analysis. Furthermore impossible
scores (e.g. VFT score after 60 s which is less than after
15 s) are also set to missing.
When baseline VFT and TMT scores are very low,
deterioration over time cannot be reliably assessed due to
floor effects. Therefore, patients with a baseline VFT score
below 3 will not be considered for longitudinal analysis on
the VFT and patients with a TMT ratio z-score of 2 or
higher at baseline not for the longitudinal analyses on the
TMT. In this case the composite score for attention and
executive functioning is just based on the valid data.
Cognitive outcomes
The primary outcome of CAROLINA®-cognition is the
occurrence of accelerated cognitive decline at end of
follow-up (a dichotomous outcome measure; presence
or absence of accelerated cognitive decline).
Secondary cognitive outcomes are assessed as follows:
 The actual change in cognitive performance at end
of follow-up (i.e. a continuous outcome measure;
change in performance from baseline).
 The proportion of participants with accelerated
cognitive decline after 160 weeks of follow-up.
 The actual change in cognitive performance after
160 weeks of follow-up (i.e. a continuous outcome
measure; change in performance from baseline).
Primary outcome considerations
Conceptually, there are different ways to define acceler-
ated cognitive decline. A fixed cut-off (e.g. occurrence of
MMSE <24 at time point of assessment) or a minimal
amount of decline (e.g. occurrence of >4 points of
decline from baseline) can be used. However, a fixed
cut-off does not take baseline performance into account
and an absolute decline does not account for important
individual factors influencing cognitive decline, such as
education. We therefore choose to use a regression
based index score (RBI score) of cognitive change over
time. This RBI score adjusts for potential confounders as
age, language, education, baseline performance, and
regression to the mean on an individual participant basis
[36]. In addition, the RBI also reduces the impact of learn-
ing effects: repeated neuropsychological assessment can
cause practice effects, both material-specific effects and the
fact that a person is no longer “test-naïve” after the first
neuropsychological assessment. While the latter cannot be
prevented, the former is countered by the use of RBI.
Accelerated cognitive decline in the CAROLINA® cognition
substudy is defined as a score at or below the 16th percent-
ile (the equivalent of approximately one standard deviation
below the mean) on the MMSE- or the A&E RBI z-score.
To convert MMSE and A&E z-scores into RBI scores, pre-
dicted follow-up scores (FUpredict) are calculated for each
individual by means of an ANCOVA model. This model
includes the following covariates: the individual’s baseline test
performance, age, years of formal education, gender, race,
and test–retest interval. Subsequently the RBI scores are
calculated for each individual by comparing his/her actual
observed cognitive (FUobserved) score to his/her predicted
cognitive score (RBI-score = (FUobserved – FUpredict)/
standard deviation (SD) of residuals). Hence, a negative
RBI-score reflects a decline in cognitive function
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(relative to the other study participants) faster than
expected (based on the adjusted covariates).
Clearly, dichotomizing the cognitive test results for the
primary outcome measure does have implications for
the analyses. It is also different from the approach of
previous studies in the field [10–13]. Of note, our ration-
ale for the dichotomy is that it has become apparent that
cognitive decline in older individuals with T2DM is
clearly not a unitary construct [2]. On average – at the
group level - cognition declines only very slowly over
time [10–13]. Yet, there is a subset of individuals with
accelerated decline [2]. While ideally this accelerated
cognitive decline would be defined in terms of incident
dementia or mild cognitive impairment, this was not
deemed to be feasible in the present multinational, mul-
ticenter study, because of variability in diagnostic ap-
proaches. We therefore choose the pragmatic approach
as described above, which is likely to capture the pa-
tients with the worst cognitive outcome, although not in
terms of a fixed diagnostic construct. Dichotomizing the
cognitive test results based on the RBI could result in an
underestimation of the standard error of the primary es-
timate of group difference in rate of cognitive decline. It
also comes at the expense of information loss and
power. Yet, it was decided to sacrifice some statistical
power in order to enable the possibility of having a more
powerful statement at the end of the trial. Moreover, the
actual change in cognitive performance at end of follow-
up (i.e. change in performance from baseline as a con-
tinuous measure) is an additional predefined outcome
measure to confirm the results of the primary analysis.
Time windows
The time from baseline to end of follow-up cognitive as-
sessment will vary between participants as patients were
recruited over a period of two years. Furthermore, as
visits may be rescheduled and each patient is followed
up for a different time interval as per study design time
windows were defined to assign each cognitive assess-
ment to either baseline, week 160 or end of follow-up.
Baseline cognitive assessments were planned to be
conducted at the day of randomisation, prior to intake
of the first dose of study drug. The first follow-up as-
sessment is scheduled after 160 weeks of follow-up (a
time window up to 166 weeks is accepted) and the final
cognitive assessment is scheduled within seven days after
the last intake of study medication.
In practice the baseline test was conducted between
Dec 2010 – Dec 2012 and the planned week 160 test
was conducted between Dec 2013 – Jan 2016. The for-
mal end of the trial will be determined in time, by reach-
ing the predefined number of patients with primary
endpoint events in the mother-trial, estimated to occur
in Q2 2018. All patients that are still on treatment by
then have their end of follow-up assessment at that time
point. Patients that stop their treatment before the end
of the trial will have their end of follow-up assessment at
that moment. For all participants with a cognitive assess-
ment after week 166, this assessment will be assigned to
the second time interval (end of follow-up).
Other study parameters
Demographics at baseline (full definitions listed in
Additional file 2)
Demographic information is collected at baseline and in-
clude age, gender, years of formal education, race (Black/
African American, White, Asian, American Indian/Al-
aska Native, Hawaiian/Pacific Islander), ethnicity (La-
tino/Hispanic, non-Latino/Hispanic), medication use,
medical history, and alcohol use.
Diabetes-related variables
Blood samples are drawn at baseline and at the day of
the first and second cognitive follow-up assessments and
include, HbA1c, FBG, and C-peptide. Samples are always
taken after an overnight fast (at least 10 h after the last
meal) and all blood samples are analysed at a central la-
boratory using validated assays. Medical history is re-
corded in the case report form (CRF) and includes
duration of diabetes and presence of diabetic complica-
tions (diabetic neuropathy, diabetic foot and proliferative
retinopathy; full definitions listed in Additional file 2).
Previous medication use, including SU or glinide is re-
corded. Episodes of hypoglycaemia, including severe
hypoglycaemic episodes, are recorded prospectively.
Cardiovascular risk profile (full definitions listed in
Additional file 2)
Cardiovascular risk factors are assessed at baseline and
at the day of the first and second cognitive follow-up
assessments. They include: smoking habits, systolic and
diastolic blood pressure, body mass index (BMI), waist
circumference, a lipid panel (total cholesterol, high dens-
ity lipoprotein (HDL) cholesterol, low density lipoprotein
(LDL) cholesterol, triglycerides), and assessment of renal
function/albuminuria. Blood pressure is measured using
either a standard mercury sphygmomanometer or an
electronic device after five minutes of rest. Weight
measurements are standardised and similar scales are
used at each visit. Waist circumference is measured in
the midpoint between the lowest rib and the iliac crest
using a non-elastic tape, after the patient exhaled. Esti-
mated glomerular filtration rate is calculated using the
Modification of Diet in Renal Disease (MDRD) formula.
History of macrovascular disease includes: ischemic
heart disease, cerebrovascular disease and peripheral
arterial occlusive disease. Cardiovascular events are
recorded prospectively.
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Statistical analysis
Sample size considerations
Accelerated decline is defined as an RBI score within the
lowest 16% for the MMSE and/or the A&E RBI score. It
is expected that an estimated of 20-22% will meet this
criterion for the primary cognitive outcome measure of
CAROLINA®. There were no formal power calculations
performed for this substudy. However with 4500 partici-
pants, approximately 900–1000 participants will thus
meet this primary cognitive outcome measure, which
will allow, at a reasonable power, a detection of a
hypothesised relative risk reduction with linagliptin for
accelerated cognitive decline of approximately 20%
(power 0.8; alpha 0.05, two-sided testing).
Primary analysis
The primary analysis will be performed in all patients
randomised and treated with at least one dose of study
drug, who have a baseline assessment and at least one
follow-up cognitive assessment available (of which at
least one of the two RBI scores can be calculated). In
this modified intention to treat analysis the proportion
of participants with accelerated cognitive decline will be
compared between the two treatment groups at end of
follow-up using a logistic regression analysis with factor
for treatment. The odds ratio (OR) along with the 95%
Wald confidence interval (CI) and the two-sided p-value
for treatment comparison will be presented.
Predefined subgroup analyses
The primary outcome will be analysed in the following
subgroups to explore the consistency of the treatment
effect: gender (male, female), age (<70, ≥70 years), race
(black, white), ethnicity (Latino/Hispanic, non-Latino/
Hispanic), CES-D (score < 16, ≥ 16 and median split),
cardiovascular risk groups (based on inclusion criterion
groups A, B, C, D; see Table 1) and duration of diabetes
(<=1 year, >1 to <=5 years, >5 to <=10 years, >10 years).
Handling of missing cognitive data
Missing baseline cognitive data will not be imputed. For
missing data due to incomplete testing, the remaining
test scores will be used to judge if accelerated cognitive
decline is present. If one of the VFT subscores is miss-
ing, the remaining scores will be used to calculate the
overall score. If either the TMT A or the TMT B is miss-
ing no TMT ratio will be calculated. If either the VFT
overall z-score or the TMT ratio is missing the
remaining score will be used to calculate the A&E score
at baseline and follow-up.
If one follow-up assessment is completely missing it
will be replaced by her/his last observed post-
randomization measurement or linearly intrapolated in
case of a missing assessment in between assessments.
If a cognitive test is not done or not completed, the in-
vestigator or research assistant should indicate whether
this was due to the inability of the patient to understand
the instructions. If this is the case at an follow-up visit
and neither the MMSE nor the A&E RBI-score can be
calculated due to missing values, the patient is classified
as having accelerated cognitive decline.
Sensitivity analyses for the primary outcome
To test the robustness of the results, sensitivity analyses
will be performed for the primary outcome (for the
second FU assessment), as shown in Table 2.
Secondary analyses
To investigate potential early treatment effect, we will
also look into the occurrence of accelerated cognitive
decline at week 160, i.e., the first cognitive assessment
post baseline.
In addition, to determine whether the definition we
used for accelerated cognitive decline influenced the
results, we will investigate the following alternative defi-
nitions for accelerated cognitive decline at week 160 and
end of follow-up:
– having a score at or below the 16th percentile on
the MMSE- or the A&E z-score (i.e. without using
RBI scores).
– having a score at or below the 10th (instead of the
16th) percentile on the MMSE- or the A&E RBI-
score
– having a follow-up MMSE score of <24 or a decline
of >4 points in MMSE relative to baseline
To investigate the actual change in cognitive perform-
ance over time, the change in z-scores for all individual
test scores (from baseline to first and second follow-up
assessment) will be analysed. This will be done using a
restricted maximum likelihood (REML) based mixed
model repeated measures (MMRM) approach. The
primary comparison will be the difference in adjusted LS
means between the two treatment groups.
Finally, to investigate the effect of treatment on the
occurrence of depression, the occurrence of a CES-D
score of ≥16 will be analysed for the first and second
follow-up assessments. This will be done using a logistic
regression analyses, as for the primary outcome.
Exploratory analyses of risk factors for cognitive
dysfunction
Additional analyses are planned to investigate the associ-
ation between mood, diabetes-related factors, and
cardiovascular factors and cognitive dysfunction. Cross-
sectional baseline analyses will be conducted aimed at
answering etiologic questions. Longitudinal analyses will
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be performed exploring both etiologic and prognostic
questions in relation to cognitive decline.
Linear regression analyses will be used for the baseline
analysis including the MMSE score and the A&E z-score
as the cognitive outcome measures. These analyses will
be adjusted for age, gender, years of formal education
and race. If a significant association is found for a
certain variable (e.g. HbA1c levels) other covariates may
be added stepwise to the model to investigate this rela-
tion further. Non-linear associations will also be consid-
ered. We will perform subgroup analyses stratified by
age (<70, ≥70 years) and gender (male, female). Similar
approaches will be taken for etiologic longitudinal ana-
lyses, using a restricted maximum likelihood based
mixed model repeated measures approach.
Since all of these secondary analyses are considered of
exploratory nature, no correction for multiple testing
will be made.
Discussion
The CAROLINA® trial provides a unique opportunity to
investigate the effect of treatment with linagliptin com-
pared to the SU glimepiride on the occurrence of acceler-
ated cognitive decline in patients with T2DM. The large
sample size, the long follow-up period and the study
population of middle aged and older (mean age 64.7 ±
9.4 years) individuals at elevated cardiovascular risk, offer
an excellent cohort to study cognitive outcomes. With the
primary outcome measure occurrence of accelerated cog-
nitive decline the cognition study focuses on those indi-
viduals who suffer from cognitive problems; a novel and
very clinically meaningful approach.
CAROLINA®-cognition, a substudy of the CARO-
LINA® trial, is the first large RCT that will yield import-
ant information regarding DPP-IV inhibitor versus SU
treatment in the reduction of accelerated cognitive
decline in patients with T2DM. A positive result in
CAROLINA®-cognition could provide important leads
towards a new prevention strategy for dementia in
T2DM and as such have major clinical T2DM treatment
ramifications.
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